Cargando…

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study

SUMMARY: BACKGROUND: The use of opioid analgesics for patients with chronic nonmalignant pain is becoming more widely accepted, and long-acting formulations are an important treatment option. AIM: To assess conversion to extended-release OROS® hydromorphone from previous stable opioid agonist therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallace, M, Rauck, R L, Moulin, D, Thipphawong, J, Khanna, S, Tudor, I C
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2007
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040191/ https://www.ncbi.nlm.nih.gov/pubmed/17877652 http://dx.doi.org/10.1111/j.1742-1241.2007.01500.x

Ejemplares similares

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(® )hydromorphone in patients with chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2009)

Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain
por: Hale, Martin E, et al.
Publicado: (2013)

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012)

A randomized, double-blind comparison of OROS(® )hydromorphone and controlled-release morphine for the control of chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2008)

Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
por: Park, Cheol Kyu, et al.
Publicado: (2016)

Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
por: Devarakonda, Krishna, et al.
Publicado: (2013)

Pharmacokinetic profile of a 24-hour controlled-release OROS(® )formulation of hydromorphone in the presence and absence of food
por: Sathyan, Gayatri, et al.
Publicado: (2007)

A new extended release formulation (OROS(®)) of hydromorphone in the management of pain
por: Weinstein, Sharon M
Publicado: (2009)

Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone
por: Sathyan, Gayatri, et al.
Publicado: (2007)

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
por: Philis-Tsimikas, Athena, et al.
Publicado: (2013)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form
por: Tiankanon, Kanitha, et al.
Publicado: (2022)

Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure
por: Puhto, Terhi, et al.
Publicado: (2020)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Medical Cannabis for Chronic Nonmalignant Pain Management
por: Hameed, Maha, et al.
Publicado: (2023)

Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
por: Shin, Seong Hoon, et al.
Publicado: (2014)

Recrudescence of Focal Stroke Symptoms during Pain Management with Hydromorphone
por: Bernstock, Joshua D., et al.
Publicado: (2016)

Hydromorphone Prescription for Pain in Children—What Place in Clinical Practice?
por: Rodieux, Frédérique, et al.
Publicado: (2022)

The use of once-daily dosing of gentamicin in obstetrics and gynecology.
por: Wiesenfeld, H C, et al.
Publicado: (1998)

Nonmalignant leukocyte disorders
por: Marionneaux, Steven
Publicado: (2020)

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
por: Zaltzman, Alina S. R, et al.
Publicado: (2016)

The Economic Impact of Opioid Use in the Management of Chronic Nonmalignant Pain
por: Lipman, Arthur, et al.
Publicado: (2015)

Erratum: Hydromorphone prescription for pain in children—What place in clinical practice?
Publicado: (2023)

The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis.
por: Sunyecz, J A, et al.
Publicado: (1998)

Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patients
por: van Maarseveen, Erik, et al.
Publicado: (2015)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Acute suicidal ideations responsive to hydromorphone
por: Rotchford, James Kimber
Publicado: (2019)

Unintentional administration of intra‐articular hydromorphone
por: Doyle, Stephen, et al.
Publicado: (2021)

Analgosedation: The Use of Fentanyl Compared to Hydromorphone
por: Choi, Hahnl, et al.
Publicado: (2021)

Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox
por: Kristensen, Niels Rode, et al.
Publicado: (2022)

Cost of Pain Medication to Treat Adult Patients with Nonmalignant Chronic Pain in the United States
por: Rasu, Rafia S., et al.
Publicado: (2014)

A randomized trial of once daily versus twice daily dosing of oral iron in CKD
por: Sood, Vivek, et al.
Publicado: (2023)

Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST (®): SIMPLE USE)
por: Park, S. W., et al.
Publicado: (2016)

Efficacy and safety of once daily dosing of colistin to critically ill patients
por: Skiada, A, et al.
Publicado: (2010)

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
por: Washington, Samuel L, et al.
Publicado: (2010)

A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee
por: Vojtaššák, Jozef, et al.
Publicado: (2011)

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
por: Balk, Jiska M, et al.
Publicado: (2015)

Chronic non-cancer pain: Focus on once-daily tramadol formulations
por: Coluzzi, Flaminia, et al.
Publicado: (2007)

A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients
por: Inoue, Satoshi, et al.
Publicado: (2018)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lub0e7u22mlfqe772cu210t73g